Mary Ellen Capuano, in Lewes, DE - Technician/Technologist

Mary Ellen Capuano, is a Technician/technologist physician based in Lewes, Delaware. Mary Ellen Capuano is licensed to practice in New Jersey (license number 626179) and her current practice location is 424 Savannah Rd, Lewes, Delaware. She can be reached at her office (for appointments etc.) via phone at (302) 645-3300.

NPI number for Mary Ellen Capuano is 1679133961 and her current mailing address is Po Box 788, Pomona, New Jersey. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1679133961.

Contact Information

	Mary Ellen Capuano,
	424 Savannah Rd, Lewes, DE 19958-1462
	(302) 645-3300
	Not Available

Physician's Profile

Full Name	Mary Ellen Capuano
Gender	Female
Speciality	Technician/technologist
Location	424 Savannah Rd, Lewes, Delaware
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1679133961
Provider Enumeration Date: 06/18/2019
Last Update Date: 06/18/2019

Medical Identifiers

Medical identifiers for Mary Ellen Capuano such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1679133961	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2085R0204X	Radiology - Vascular & Interventional Radiology	626179 (New Jersey)	Secondary
156F00000X	Technician/technologist	626179 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mary Ellen Capuano is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mary Ellen Capuano, Po Box 788, Pomona, NJ 08240-0788 Ph: () -	Mary Ellen Capuano, 424 Savannah Rd, Lewes, DE 19958-1462 Ph: (302) 645-3300

News Archive

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

'Large-scale action' needed in Myanmar to prevent spread of artemisinin-resistant malaria parasites

In this New York Times opinion piece, Frank Smithuis, director of Medical Action Myanmar in Yangon, and Nick White, professor of tropical medicine at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, recount a brief history of the development of anti-malaria drugs and their contribution to "a significant global reduction in malaria" and note that this progress "is now threatened by the emergence of malaria parasites that are resistant to artemisinin on the Cambodia-Thailand border ..., the same place where chloroquine resistance emerged 50 years ago and spread across Asia and Africa to claim millions of lives."

TSRI scientists discover how key protein establishes proper vision

Scientists from the Florida campus of The Scripps Research Institute have discovered how a protein called α2δ4 establishes proper vision.

Scientists suppress NCoR1 protein and create mighty mice

A team of researchers at EPFL, the University of Lausanne and the Salk Institute created super strong, marathon mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach.

SARS-CoV-2 limits type I and type III IFN protein biogenesis

New research led by Roy Parker of the University of Colorado Boulder finds that SARS-CoV-2 prevents the IFN response despite an increased presence of IFN-encoding mRNAs by suppressing transcriptional processes. Inhibition of IFN mRNAs triggers degradation from the activation of RNase L and the SARS-CoV-2 protein Nsp1.

Mary Ellen Capuano, - Technician/Technologist in Lewes, DE